A New Hope in Alzheimer’s Care: India Gets Lormalzi®

General
1

Eli Lilly launches once-monthly Alzheimer drug Lormalzi in India

Global pharma giant Eli Lilly has launched Lormalzi® (donanemab) in India — a once-monthly therapy for patients with early-stage Alzheimer’s disease. This marks India’s first approved amyloid plaque-targeting treatment for Alzheimer’s.

How does it work?
Lormalzi is designed to remove amyloid plaques in the brain — abnormal protein deposits associated with memory decline and cognitive impairment. By targeting these plaques, the drug may help slow disease progression in patients with mild cognitive impairment or mild dementia due to Alzheimer’s disease.

Benefits-
• Once-monthly IV infusion
• Approved for early symptomatic Alzheimer’s disease
• Focuses on disease modification rather than only symptom relief

India currently has an estimated 8.8 million people living with dementia, and this number is expected to rise significantly in the coming years. The launch of newer therapies may improve awareness, early diagnosis, and treatment access.

:speech_balloon: Do you think disease-modifying therapies like donanemab can change the future of Alzheimer’s care in India?

MBH/PS

2 Likes
2

till now, we have heard that there is no such cure of this disease physiostigmine was the sole drug that i read

I hope this drug will be the healer

1 Like
3

Interesting read.

4

Great to see advancements focusing on the root cause rather than just symptoms. This could be a game-changer for early Alzheimer’s management

6

Very informative post.

7

Thank you for this informative post. As i said medicine is ever evolving. Positive outcomes might give a hope for Dementia and Alzheimer’s patients.

8

Informative.

9

The introduction of Lomalzi in India represents a promising step forward in Alzheimers treatment.For years, Alzheimers care mainly revolved around supportive treatment and symptom management, so a therapy that specifically targets amyloid plaques is an important scientific advancement.

10

I do believe disease modifying therapies can work so much better to treat such disorders.The only concern that remains is that neurological disorders have certain limitations to their studies certain parts remain unexplored owing to the complexity.So even though future of Alzheimer care can be improved there are still many challenges in the way.